Key terms
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BTAI news
Apr 16
6:31am ET
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)
Apr 16
6:30am ET
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)
Apr 15
6:48am ET
BioXcel Therapeutics price target lowered to $10 from $11 at H.C. Wainwright
Apr 15
6:16am ET
Buy Rating Affirmed for Bioxcel Therapeutics Amid Strategic Clinical Trials and Regulatory Potential
Mar 25
7:13am ET
BioXcel Therapeutics announces $25M registered direct offering
Mar 24
2:01am ET
Bioxcel Therapeutics Faces Market Estimation Risks Amidst Adoption and Access Challenges
Mar 19
8:45am ET
Largest borrow rate increases among liquid names
Mar 18
6:26am ET
Buy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 Expansion
Mar 15
8:45am ET
Largest borrow rate increases among liquid names
Mar 15
7:09am ET
BioXcel Therapeutics announces European Patent Office grant
Mar 13
7:32am ET
BioXcel Therapeutics price target lowered to $7 from $8 at BofA
Mar 13
6:39am ET
Buy Rating Affirmed for BioXcel Therapeutics Amid Label Expansion and Strong Clinical Prospects
Mar 12
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 12, 2024
Mar 12
7:09am ET
BioXcel Therapeutics provides updates on clinical programs for BXCL501
Mar 12
7:07am ET
BioXcel Therapeutics expects cash to fund operations through mid-2024
Mar 12
7:07am ET
BioXcel Therapeutics reports Q4 EPS (76c), consensus (91c)
Mar 01
8:45am ET
Largest borrow rate increases among liquid names
Feb 28
8:45am ET
Largest borrow rate increases among liquid names
Feb 21
7:26am ET
BioXcel Therapeutics downgraded to Neutral from Buy at UBS
Feb 13
5:23am ET
Maintaining Hold Rating on Bioxcel Therapeutics Amid Financing Positives and Extended Clinical Timelines
Feb 12
1:03pm ET
Bioxcel Therapeutics Enhances Financial Position and Progresses in Cancer Treatment
Feb 12
11:09am ET
Biotech Alert: Searches spiking for these stocks today
Feb 12
7:17am ET
BioXcel receives Fast Track designation from FDA for BXCL701
Feb 09
5:05am ET
BioXcel Therapeutics Eyes Phase 3 Trials Amid Financial Woes
Feb 09
4:10am ET
Bioxcel Therapeutics Secures Patents for Agitation Treatments
Feb 08
4:07pm ET
BioXcel Therapeutics announces $60M common stock offering
Feb 08
11:40am ET
Biotech Alert: Searches spiking for these stocks today
Feb 07
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 06
7:07am ET
BioXcel Therapeutics completes patient enrollment in Phase 2 trial of BXCL701
Feb 06
6:26am ET
Buy Rating on BioXcel Therapeutics Backed by Patent Strength and Upcoming Clinical Milestones
Feb 05
8:28pm ET
BioXcel Therapeutics: Strong Buy Rating on Patent Protections and Strategic Advancements
No recent press releases are available for BTAI
BTAI Financials
Key terms
Ad Feedback
BTAI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BTAI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
